Current Therapeutic Strategies for Chagas Disease

Trypanosoma cruzi, the parasite that causes Chagas disease, can only be cured with one of two drugs, benznidazole or nifurtimox. The main disadvantages of these drugs include their ineffectiveness outside of the acute or early infection phase, their unpleasant effects, and the parasite's tolerance to their activities. On the other hand, several institutions and research groups have been working on a number of ways that can help find a solution to the problem. These strategies have evolved over the last few years. Several examples of such advancements include the utilization of combination therapy, the repurposing of current treatments, and the change of dosages for traditional drugs. Research has also been conducted on antiparasitic plants and the substances that may be obtained from them, and it makes use of existing knowledge gathered through medical procedures. Some works have studied the parasite in order to identify important genes that have the potential to be used as therapeutic targets in the development of novel targeted medications. Even though a lot of these studies have shown promising results, only a small fraction of them make it to the clinical testing phase of the study. Institutions and research organizations should be rewarded for coordinating their efforts and addressing all areas of drug development, given their resources and information. Last but not least, distributing this information will result in novel Chagas disease therapies, which would assist impacted populations.